$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
克唑替尼治疗非小细胞肺癌后肾脏并发症的影像学特征:病例报告
2025-10-19 11:44:20
Check Details
接受克唑替尼治疗的肺癌生存者圆生子梦
2025-10-19 11:44:20
Check Details
EGFR突变ALK重排共存突变晚期非小细胞肺癌患者的临床结果
2025-10-19 11:44:20
Check Details
累积吸烟量影响EGFR突变肺腺癌患者靶向药治疗结果:回顾性研究
2025-10-19 11:44:20
Check Details
克唑替尼治疗出现附件转移的ALK重排肺腺癌患者:病例报告
2025-10-19 11:44:20
Check Details
ERBB突变与阿法替尼或厄洛替尼治疗肺鳞癌患者临床结果:LUX-Lung 8试验
2025-10-19 11:44:20
Check Details
阿法替尼vs吉非替尼或厄洛替尼治疗EGFR突变非小细胞肺癌
2025-10-19 11:44:20
Check Details
克唑替尼治疗难治性ALK阳性间变性T细胞淋巴瘤3年持续完全反应
2025-10-19 11:44:20
Check Details
克唑替尼使IHC ALK阳性FISH阴性肺癌患者获益
2025-10-19 11:44:20
Check Details
克唑替尼成功治疗ALK阳性非小细胞肺癌伴双侧乳腺转移
2025-10-19 11:44:20
Check Details
阿法替尼vs其他激酶抑制剂作为EGFR突变非小细胞肺癌一线治疗
2025-10-19 11:44:20
Check Details
克唑替尼治疗ALK阳性间变性大细胞淋巴瘤伴肾功能不全1例
2025-10-19 11:44:20
Check Details
1
2
...
3040
3041
3042
3043
3044
3045
3046
...
4161
4162
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
2
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
3
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
4
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
5
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
6
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance
7
Lorlatinib Contraindications and Safety Warnings: Six Key Risks to Monitor
8
Dacomitinib for EGFR-Mutant NSCLC: Dosing, Switching, and Safety Profile
9
Abemaciclib for HR+ HER2- Breast Cancer: Mechanism, Combination Therapy, and Switching Considerations
10
Cemiplimab Mechanism of Action: How PD-1 Inhibition Restores Antitumor Immunity
11
Tivozanib Dosing Guide for Renal Cell Carcinoma: 21-Day On/7-Day Off Cycle and Adjustments
12
Selpercatinib: Dosing and Administration Essentials of an Oral RET Inhibitor